1. Home
  2. CVKD

as 10-09-2025 3:51pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Founded: 2022 Country:
United States
United States
Employees: N/A City: PONTE VEDRA
Market Cap: 27.0M IPO Year: 2023
Target Price: $32.00 AVG Volume (30 days): 28.8K
Analyst Decision: Strong Buy Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -8.62 EPS Growth: N/A
52 Week Low/High: $8.74 - $22.90 Next Earning Date: 11-06-2025
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

CVKD Daily Stock ML Predictions

Stock Insider Trading Activity of Cadrenal Therapeutics Inc. (CVKD)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Szot Matthew K CVKD Chief Financial Officer Oct 6 '25 Sell $13.99 107 $1,496.93 17,026
Pham Quang X CVKD CEO and Chairman Oct 1 '25 Sell $14.01 881 $12,342.81 202,633
Szot Matthew K CVKD Chief Financial Officer Oct 1 '25 Sell $13.99 1,700 $23,783.00 17,026
Pham Quang X CVKD CEO and Chairman Sep 29 '25 Sell $14.01 419 $5,870.19 202,633
Szot Matthew K CVKD Chief Financial Officer Sep 29 '25 Sell $14.00 100 $1,400.00 17,026

Share on Social Networks: